While up to 80% of dysplasias with FCD2 pathology show activating PI3K-mTOR variants (9), how the genetic variants affect cell identities and states in the brain, and how these effects might lead to drug-resistant epilepsy, is unclear. This evidence concerns the gene TCF4 and epilepsy.